Overview
P4 (Pregabalin for Peripheral Posttraumatic Pain)
Status:
Completed
Completed
Trial end date:
2008-05-01
2008-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate the efficacy of pregabalin compared to placebo in the treatment of posttraumatic peripheral neuropathic painPhase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Treatments:
Pregabalin
Criteria
Inclusion Criteria:- Diagnosis of Posttraumatic Peripheral Neuropathic Pain (NeP) syndrome, including
post-surgical NeP, NeP due to peripheral nerve injury, and phantom limb pain,
confirmed by a qualified pain specialist and persisting for a minimum of 3 months
following the traumatic event
Exclusion Criteria:
- Subjects whose posttraumatic neuropathic pain is due to Complex Regional Pain Syndrome
(CRPS, Type I or Type II)
- NeP not due to trauma, and not peripheral pain